Trial Profile
Cost-effectiveness of subcutaneous anti−tumour necrosis factor therapy in patients with psoriatic arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2012
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Methotrexate (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 05 Apr 2012 New trial record
- 20 Mar 2012 Results presented at the 70th Annual Meeting of the American Academy of Dermatology.